سعر فرستليس 12.5مجم 10 اقراص 2022

Film-coated tablets containing tianeptine sodium 12.5 mg, an antidepressant, made by Delta Pharma; pack of 10 tablets.

• Major depressive episodes.Population: AdultsBase de Donnees Publique des Medicaments (French Ministry of Health / ANSM)

• Mainly nausea, constipation, abdominal pain, somnolence, headache, dry mouth and dizziness; also common: anorexia, nightmares, insomnia.International label, equivalent formulation · Base de Donnees Publique des Medicaments (French Ministry of Health / ANSM)
• Uncommon: abuse and dependence (especially under 50 years with a history of drug or alcohol dependence). Frequency not known: hyponatraemia, suicidal ideas or behaviour, confusion, hallucinations.International label, equivalent formulation · Base de Donnees Publique des Medicaments (French Ministry of Health / ANSM)

• Hypersensitivity to tianeptine or any excipient.International label, equivalent formulation · Base de Donnees Publique des Medicaments (French Ministry of Health / ANSM)
• Children and adolescents under 15 years.International label, equivalent formulation · Base de Donnees Publique des Medicaments (French Ministry of Health / ANSM)

• Suicidal thoughts and behaviour: monitor closely, especially early in treatment, after dose changes and in patients under 25 or with a history of suicidal behaviour.International label, equivalent formulation · Base de Donnees Publique des Medicaments (French Ministry of Health / ANSM)
• Abuse and dependence can occur, particularly in patients with a history of drug or alcohol dependence; do not exceed recommended doses. Withdrawal symptoms (anxiety, muscle, abdominal and joint pain, insomnia) may follow stopping.International label, equivalent formulation · Base de Donnees Publique des Medicaments (French Ministry of Health / ANSM)
• Hyponatraemia, probably due to SIADH, has been reported, mainly in elderly patients; use caution in the elderly, in cirrhosis, dehydration or with diuretics.International label, equivalent formulation · Base de Donnees Publique des Medicaments (French Ministry of Health / ANSM)

• Irreversible MAO inhibitors (e.g. iproniazid)Combination not recommended because of risk of collapse or paroxysmal hypertension, hyperthermia, convulsions and death. Allow 2 weeks after stopping an MAOI before starting tianeptine, and 24 hours after stopping tianeptine before starting an MAOI.Base de Donnees Publique des Medicaments (French Ministry of Health / ANSM)

• Limited data (fewer than 300 pregnancies); it is preferable to avoid tianeptine throughout pregnancy. If treatment is needed to keep the mother stable, use an effective dose, preferably as monotherapy, and monitor the newborn.International label, equivalent formulation · Base de Donnees Publique des Medicaments (French Ministry of Health / ANSM)
• Breastfeeding is not recommended during treatment (tricyclic antidepressants are excreted in breast milk).International label, equivalent formulation · Base de Donnees Publique des Medicaments (French Ministry of Health / ANSM)

English text not available for this section.